Hematologic Malignancies
We recommend
Addition of ixazomib to lenalidomide and dexamethasone in multiple myeloma − Data from real-world Czech practice
A group of Czech and Slovak experts led by Associate Professor Jiří Minařík from the Hemato-Oncology Clinic of the Faculty of Medicine UP and University Hospital Olomouc published the final results of an observational study evaluating the addition of ixazomib to the combination with lenalidomide and dexamethasone in patients with relapsing/refractory multiple myeloma (RRMM). This involves experiences from real clinical practice, with data obtained from the Czech Registry of Monoclonal Gammopathies.
Consolidation therapy with brentuximab vedotin after autologous stem cell transplantation in patients with relapsed/refractory Hodgkin lymphoma
At the 12th International Symposium on Hodgkin Lymphoma (ISHL), held in October 2022 in Cologne,…
Brentuximab vedotin in combination with lenalidomide and rituximab in R/R DLBCL – results from the open part of the ECHELON-3 study
The aim of the open run-in phase of the randomized placebo-controlled phase III ECHELON-3 study,…
Articles on this topic
6-year data from the ECHELON-1 study: How does combining brentuximab vedotin with chemotherapy affect overall survival of previously untreated cHL patients?
At this year's annual congress of the European Hematology Association (EHA), results from the…
Brentuximab Vedotin in Patients with R/R cHL in the Real World: What to Expect?
How does brentuximab vedotin (BV) perform as maintenance therapy in real-world practice for…
What Response to the COVID-19 Vaccine Can Be Expected in Patients After Stem Cell Transplantation?
During the recent virtual congress of the European Society for Blood and Marrow…
PHD 2022: In the treatment of multiple myeloma we have achieved significant progress, confirm real-world data
The treatment options for multiple myeloma (MM) have significantly advanced over the past 10…
Hodgkin Lymphoma in a Summary of News from Post-ASH 2021
Dr. Anna Suredová from the Clinical Hematology Department of the Catalonian Oncology Institute…
Current Treatment Options for Multiple Myeloma
Multiple myeloma (MM) accounts for about 10% of all hematologic malignancies. Thanks to…
In decisions about therapeutic strategy in multiple myeloma, patient preferences and concerns also play a crucial role
The perspective on the preferences of patients with multiple myeloma (MM) is very necessary at…
Brentuximab Vedotin as Another Therapeutic Option in Cutaneous T-Cell Lymphoma
Current systemic treatment for patients with cutaneous T-cell lymphoma (CTCL) unfortunately…
Bite-Sized Pieces from EHA 2021: Two New Findings on T-Cell Lymphoma
Can a molecule that is crucial for the sensitivity of adult T-cell lymphoma or leukemia (ATLL)…
Benefit of ixazomib in patients with relapsed/refractory multiple myeloma in routine clinical practice
The results of treating relapsed or refractory multiple myeloma in real-world routine clinical…
1
2
Subscribe
Most read on this topic
Related topic
Most read on this topic
- Hodgkin lymphoma – endless story
- Non-Hodgkin lymphomas in the Czech Republic
- Current Treatment Options for Multiple Myeloma
- PHD 2022: In the treatment of multiple myeloma we have achieved significant progress, confirm real-world data
- Hodgkin Lymphoma in a Summary of News from Post-ASH 2021
- 6-year data from the ECHELON-1 study: How does combining brentuximab vedotin with chemotherapy affect overall survival of previously untreated cHL patients?
Related topic